Cambinol is primarily studied for its biological activity in cellular regulation and disease models. It acts as an inhibitor of histone acetyltransferases, particularly p300 and PCAF, which are involved in gene expression and cell cycle control. This inhibition makes it a useful research tool in cancer studies, where modulation of acetylation can influence tumor growth and apoptosis. It has shown potential in preclinical models for suppressing the proliferation of cancer cells, especially in hematological malignancies and solid tumors. Researchers also explore its role in blocking the NAD+-associated enzyme CD38, which may have implications in aging and metabolic disorders. Due to its ability to cross cell membranes easily, cambinol is favored in cellular assays for probing acetylation-dependent pathways. While not used clinically, it serves as a lead compound for developing more potent and selective inhibitors targeting epigenetic regulators in disease therapy.